An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-Doses to Patients With Solid Tumors.

Trial Profile

An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-Doses to Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs THR 317 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors BioInvent International
  • Most Recent Events

    • 24 Jan 2012 Results have been published in the British Journal of Cancer.
    • 17 Nov 2009 Results were presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 17 Nov 2009 Status changed from active, no longer recruiting to completed, according to a ThromboGenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top